Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

T-lineage acute lymphoblastic leukaemia (T-ALL) is a high-risk tumour that has eluded
comprehensive genomic characterization, which is partly due to the high frequency of …

The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL2
inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting …

Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled
with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute …

Lineage-ambiguous leukemias are high-risk malignancies of poorly understood genetic
basis. Here, we describe a distinct subgroup of acute leukemia with expression of myeloid, T …

Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …